MétaCan
Menu
Back to cohort
Record W1554065380 · doi:10.4081/hmr.v3i3.587

Advanced Hodgkin’s lymphoma: doxorubicin, bleomycin, vinblastine, dacarbazine and beyond

2009· article· en· W1554065380 on OpenAlexaboutno aff
Volker Diehl

Bibliographic record

VenueHematology Meeting Reports (formerly Haematologica Reports) · 2009
Typearticle
Languageen
FieldMedicine
TopicLymphoma Diagnosis and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsABVDDacarbazineMedicineVinblastineBleomycinInternal medicineOncologyNuclear medicineChemotherapyVincristineCyclophosphamide

Abstract

fetched live from OpenAlex

In 2009 patients with Hodgkin’s lymphoma in all stages and all different histologies can be cured when treated with the right therapy from the moment of diagnosis. In early stages cure is possible with 2 ABVD and 20 Gy IF-RT in nearly 97% (HD10, GHSG) and in intermediate stages with 2 BEACOPP esc + 2 ABVD + 30 Gy IF-RT in 95% (HD14, GHSG). In advanced stages (in the GHSG and EORTC/GELA only stages IIB LMM, III,IV - and not like in the USA/Canada including in advanced stages all I-II B and bulk > 5 cm, that are in the GHSG and EORTC/GELA included in the intermediate, early unfavorable stages and amount to about 30% of all patients!!!)- if you start with 6-8 courses of ABVD and add in 45% of patients additive IF-RT: you reach about 75% PFS at 5 years (Aleman et al., NEJM, EORTC). When starting with 6-8 courses of BEACOPP esc or BEACOPP-14 you reach a PFS at 5 years of 88% (HD 9;12;15, GHSG) with the higher risk of more acute toxicity and infertility and a risk of AML/MDS which is not higher than 1% (HD12;15 in about 2500 treated patients). The question now arises which group of patients with Hodgkin’s lymphoma in the true advanced stages (IIB-LMM, III-IV) can be cured when using ABVD as induction regimen and which patients need a more aggressive treatment, f.e BEACOPP esc/14. To answer this question every doctor treating Hodgkin Lymphoma patients has to balance the whole package of induction and salvage therapy to reach a long term cure with the least possible burden of acute and long term toxicity and the highest number of cures possible, optimally reached at the earliest time point, since the patient is not interested in a prolongation of hospitalization and suffering when salvage becomes necessary! The advent of the IPS and FDG-PET have now enabled doctors to tailor therapy according to their risk to develop progressive or relapsing disease and to modulate treatment according to the assessmant of an early therapy response already after 1 or 2 courses of chemotherapy. In the presentation I shall elude on the different options used nowadays in the international studies launched around the world when using only the FDG-PET as response indicator after 2 ABVD or as in the Israelian study using IPS as risk indicator and FDG-PET as response modulator. The question remains and has to be discussed intensively: will BEACOPP esc or HDCT+SCT with IGEV or DHAP after PET-2 pos after 2 ABVD not be 8 weeks too late (remember the Diehl-Kairos- Principle!!) when it would be more effective and less long term toxic to start in the high IPS- risk group with 2 BEACOPP esc and deescalate to ABVD when PET is negative already after 2 BEAesc!

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.005
Threshold uncertainty score0.018

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.255
Teacher spread0.247 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2009
Admission routes1
Has abstractyes

Explore more

Same venueHematology Meeting Reports (formerly Haematologica Reports)Same topicLymphoma Diagnosis and TreatmentFrench-language works237,207